Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Pascua, Philippe Noriel Q ^a   Song, Min Suk ^a   Lee, Jun Han ^a   Park, Kuk Jin ^a   Kwon, Hyeok il ^a   Baek, Yun Hee ^a   Hong, Seung Pyo ^b   Rho, Jong Bok ^b   Kim, Chul Joong ^c   Poo, Haryoung ^d   Ryoo, Thomas S ^e   Sung, Moon Hee ^b   Choi, Young Ki ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Bioleaders Corporation   (South Korea)

^c Chungnam National University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^e Prestige World Genetics   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CROSS REACTION; DRUG EFFICACY; FERRET; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PANDEMIC; SINGLE DRUG DOSE; SWINE; VIRUS REPLICATION; VIRUS SHEDDING; ANIMAL; ANTIBODY PRODUCTION; BODY TEMPERATURE; CROSS PROTECTION; EPIDEMIC; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA; LUNG; MINIPIG; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PHYLOGENY; SEASON; TREATMENT OUTCOME; VACCINATION; VIROLOGY; VIRUS LOAD;

ANIMALIA; MUS; MUSTELA; SUIDAE;

ANIMALS; ANTIBODY FORMATION; BODY TEMPERATURE; CROSS PROTECTION; DISEASE OUTBREAKS; FERRETS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; SEASONS; SWINE; SWINE, MINIATURE; TREATMENT OUTCOME; VACCINATION; VIRAL LOAD;

EID: 77949516890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008431     Document Type: Article

References (36)

1. Nicholls H (2006) Pandemic influenza: the inside story. PLoS Biol 4: e50.
2. Cohen J, Enserink M (2009) Swine flu. After delays, WHO agrees: the 2009 pandemic has begun. Science 324: 1496-1497.
3. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605-2615.
4. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, et al. (2009) Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 360: 2616-2625.
5. World Health Organization (2009) New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 84: 249-257.
6. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
7. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484-487.
8. Munster VJ, de WE, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325: 481-483.
9. Trifonov V, Khiabanian H, Greenbaum B, Rabadan R (2009) The origin of the recent swine influenza A(H1N1) virus infecting humans. Euro Surveill 14.
10. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
11. Brookes SM, Irvine RM, Nunez A, Clifford D, Essen S, et al. (2009) Influenza A (H1N1) infection in pigs. Vet Rec 164: 760-761.
12. Lange E, Kalthoff D, Blohm U, Teifke JP, Breithaupt A, et al. (2009) Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. J Gen Virol 90: 2119-2123.
13. OIE (2009) World Animal Health Information Database, WAHID Weekly Disease Information. Vol 22-No. 19 (May 2, 2009), No. 32 (July 31, 2009), No. 35 (August 27, 2009), and No. 39 (September 24, 2009), No 40 (September 29, 2009), No. 42 (October 12, 2009), No.43 (October 21, 2009) No. 44 (October 23,2009), No. 44 (Octobere 27, 2009) No. 45 (November 3, 2009). www.oie.int/wahis/public.php?page=weekly_report_index&admin=0.Accessed:November23,2009.
14. Castrucci MR, Donatelli I, Sidoli L, Barigazzi G, Kawaoka Y, et al. (1993) Genetic reassortment between avian and human influenza A viruses in Italian pigs. Virology 193: 503-506.
15. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, et al. (1998) Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 72: 7367-7373.
16. Scholtissek C (1995) Molecular evolution of influenza viruses. Virus Genes 11: 209-215.
17. Ma W, Kahn RE, Richt JA (2008) The pig as a mixing vessel for influenza viruses: Human and veterinary implications. J Mol Genet Med 3: 158-166.
18. Stohr K (2003) The global agenda on influenza surveillance and control. Vaccine 21: 1744-1748.
19. Centers for Disease Control and Prevention (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58: 521-524.
20. Centers for Disease Control and Prevention (2009) Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) United States, May-June 2009. MMWR Morb Mortal Wkly Rep 58: 1241-1245. mm5844a5 [pii].
21. Kelly H, Grant K (2009) Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 14.
22. Centers for Disease Control and Prevention (2009) Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58: 893-896.
23. Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus. Lab Anim (NY) 33: 50-53.
24. Pascua PN, Song MS, Lee JH, Choi HW, Han JH, et al. (2008) Seroprevalence and genetic evolutions of swine influenza viruses under vaccination pressure in Korean swine herds. Virus Res 138: 43-49.
25. Wright PF, Neumann G, Kawaoka Y (2007) Orthomyxoviruses. In: Knipe DM, Howley PM, eds (2007) Fields Virology. Philadelphia: Lippincott Williams & Wilkins. pp 1691-1740.
26. Murphy BR, Clements ML (1989) The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146: 107-116.
27. Cox RJ, Brokstad KA, Ogra P (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15. 1382 [pii].
28. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
29. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG (2002) Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20: 3165-3170.
30. Song MS, Oh TK, Pascua PN, Moon HJ, Lee JH, et al. (2009) Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. Vaccine 27: 3145-3152.
31. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903-5911.
32. Palmer DF, Dowdle WR, Coleman MT, Schild GC (1975) Advanced laboratory techniques for influenza diagnosis. Immun Ser 6: 25-45.
33. Kim JK, Seiler P, Forrest HL, Khalenkov AM, Franks J, et al. (2008) Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks. J Virol 82: 11374-11382.
34. Aiyar A (2000) The use of CLUSTAL W and CLUSTAL X for multiple sequence alignment. Methods Mol Biol 132: 221-241.
35. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
36. Perriere G, Gouy M (1996) WWW-query: an on-line retrieval system for biological sequence banks. Biochimie 78: 364-369.